Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07181109 · ClinicalTrials.gov registry record · Phase 3
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
A Phase 3 study of Hypertension and High Risk Cardiovascular Disease, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 11,000
- Enrollment target
- 20
- Study locations
NCT07181109 is a Phase 3 study of Hypertension and High Risk Cardiovascular Disease that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 11,000 participants, above the 3,484-participant average among 470 other Hypertension trials with a reported enrollment target (216% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT07181109, a Phase 3 study of Hypertension and High Risk Cardiovascular Disease, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 11,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zilebesiran
Study Locations (20)
Arizona
- Clinical Trial Site - Chandler
- Clinical Trial Site - Gilbert
- Clinical Trial Site - Glendale
- Clinical Trial Site - Mesa
- Clinical Trial Site - Phoenix
- Clinical Trial Site - Phoenix
- Clinical Trial Site - Sun City West
- Clinical Trial Site - Tucson
- Clinical Trial Site - Tucson
California
- Clinical Trial Site - Beverly Hills
- Clinical Trial Site - Chula Vista
- Clinical Trial Site - Escondido
- Clinical Trial Site - Glendale
- Clinical Trial Site - Lancaster
- Clinical Trial Site - Long Beach
Alabama
- Clinical Trial Site - Huntsville
- Clinical Trial Site - Huntsville
- Clinical Trial Site - Sheffield
Arkansas
- Clinical Trial Site - Little Rock
- Clinical Trial Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11,000 participants |
| Start Date | 2025-09-22 |
| Est. Completion | 2030-09-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07181109
The ClinicalTrials.gov registry entry for NCT07181109 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 11,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,484-participant average among 470 other Hypertension trials with a reported enrollment target (216% higher). The listed sponsor is Alnylam Pharmaceuticals, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07181109 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT07181109 about?
NCT07181109 is a clinical study titled "Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease". The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adju...
What is the current status of trial NCT07181109?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 11,000 participants. The study started on 2025-09-22. Estimated completion is 2030-09-30.
What conditions does trial NCT07181109 study?
This clinical trial studies the following conditions: Hypertension, High Risk Cardiovascular Disease, High Cardiovascular Risk.
What interventions are being tested in trial NCT07181109?
The interventions under investigation include: Placebo (DRUG), Zilebesiran (DRUG).
Who is sponsoring clinical trial NCT07181109?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07181109 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Renal Artery Denervation Assessment Without Antihypertensive Medication Regimen (RADAR)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
RECRUITING · Phase 3
-
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
RECRUITING · Phase 3
-
Open-Label Extension (OLE) Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Hypertension
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.